- 15. Have received prior treatment with chemotherapy (except for neoadjuvant/adjuvant chemotherapy), fulvestrant, any investigational-ER-directed therapy (including SERDs and non-SERDs), any PI3K-, mTOR-, or AKT-inhibitor
|
-
16. Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
|
-
17. Have inflammatory breast cancer
|
-
18. Patients with known pathogenic germline mutations who are appropriate for treatment with a PARP inhibitor, in regions where these therapies are approved and available, are not eligible for this study
|
-
19. Have visceral crisis, lymphangitic spread within the lung, or any evidence of leptomeningeal disease. Visceral crisis is not the mere presence of visceral metastases but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies,
and rapid progression of the disease
|
-
20. Have symptomatic or untreated brain metastasis. Patients with treated brain metastases are eligible for this study if they completed prior therapy (including radiation and/or surgery) =28 days prior to first dose of study treatment and are not receiving corticosteroids and/oranticonvulsants for at least 14 days prior to first dose of study treatment, and their disease is asymptomatic and radiographically stable for at least 28 days prior to consent by repeat imaging (repeat imaging should be performed during study screening)
|